Revance Therapeutics Inc. (NASDAQ:RVNC) CEO L Daniel Browne sold 6,452 shares of Revance Therapeutics stock in a transaction dated Friday, March 16th. The stock was sold at an average price of $31.64, for a total transaction of $204,141.28. Following the transaction, the chief executive officer now directly owns 130,208 shares of the company’s stock, valued at $4,119,781.12. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.
L Daniel Browne also recently made the following trade(s):
- On Wednesday, March 7th, L Daniel Browne sold 27,283 shares of Revance Therapeutics stock. The shares were sold at an average price of $31.43, for a total transaction of $857,504.69.
Shares of RVNC stock traded down $0.70 during trading hours on Friday, hitting $30.35. The company’s stock had a trading volume of 218,158 shares, compared to its average volume of 337,011. Revance Therapeutics Inc. has a 12-month low of $18.42 and a 12-month high of $37.45.
Revance Therapeutics (NASDAQ:RVNC) last announced its quarterly earnings results on Wednesday, February 28th. The biopharmaceutical company reported ($1.14) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.99) by ($0.15). Revance Therapeutics had a negative return on equity of 64.40% and a negative net margin of 46,025.57%. The firm had revenue of $0.04 million for the quarter, compared to analysts’ expectations of $0.09 million. During the same period last year, the company posted ($0.95) earnings per share. The business’s quarterly revenue was down 50.7% on a year-over-year basis. research analysts expect that Revance Therapeutics Inc. will post -3.56 EPS for the current fiscal year.
Several equities research analysts have recently commented on RVNC shares. Piper Jaffray set a $48.00 price target on shares of Revance Therapeutics and gave the company a “buy” rating in a report on Thursday, March 1st. Cantor Fitzgerald set a $50.00 price objective on shares of Revance Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, February 28th. Barclays set a $40.00 price objective on shares of Revance Therapeutics and gave the stock a “buy” rating in a research note on Tuesday, December 19th. Mizuho restated a “buy” rating and set a $54.00 price target on shares of Revance Therapeutics in a research note on Friday, January 5th. Finally, Cowen set a $55.00 price target on shares of Revance Therapeutics and gave the company a “buy” rating in a research note on Wednesday, January 17th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and twelve have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $45.17.
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. SG Americas Securities LLC acquired a new position in Revance Therapeutics during the third quarter worth $144,000. Cowen Inc. acquired a new position in Revance Therapeutics during the fourth quarter worth $225,000. Teacher Retirement System of Texas acquired a new position in Revance Therapeutics during the fourth quarter worth $255,000. Voya Investment Management LLC acquired a new position in Revance Therapeutics during the second quarter worth $274,000. Finally, Quinn Opportunity Partners LLC acquired a new position in Revance Therapeutics during the fourth quarter worth $325,000. 95.14% of the stock is currently owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY NOTICE: This piece was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright law. The correct version of this piece can be accessed at https://www.dispatchtribunal.com/2018/04/08/revance-therapeutics-inc-rvnc-ceo-sells-204141-28-in-stock.html.
Revance Therapeutics Company Profile
Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacturing, and commercialization of novel botulinum toxin products for various aesthetic and therapeutic indications. The company's drug candidate is DaxibotulinumtoxinA for injection (RT002), which is in phase III clinical trials to treat glabellar (frown) lines, as well as in phase II clinical trials for the treatment of cervical dystonia and plantar fasciitis.
Receive News & Ratings for Revance Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.